We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

48 hedge funds and large institutions have $39M invested in VistaGen Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

625% more call options, than puts

Call options by funds: $29K | Put options by funds: $4K

0.51% less ownership

Funds ownership: 55.75% → 55.24% (-0.51%)

11% less funds holding

Funds holding: 54 → 48 (-6)

13% less capital invested

Capital invested by funds: $44.9M → $39M (-$5.83M)

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

Holders
48
Holders Change
-6
Holders Change %
-11.11%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
12
Reduced
20
Closed
9
Calls
$29K
Puts
$4K
Net Calls
+$25K
Net Calls Change
+$1.33M

Top Buyers

1
IC
Ikarian Capital
Texas
+$1.48M
2
ACM
ADAR1 Capital Management
Texas
+$847K
3
BFM
Boothbay Fund Management
New York
+$440K
4
DP
Diadema Partners
New Jersey
+$349K
5
AI
AdvisorShares Investments
Maryland
+$168K

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$574K
2
Squarepoint
Squarepoint
New York
-$318K
3
UBS Group
UBS Group
Switzerland
-$302K
4
Group One Trading
Group One Trading
Illinois
-$261K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$170K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
TCG Crossover Management
California
$6.69M – – –
SC
2
Stempoint Capital
New York
$5.11M +$108K +38,062 +2%
NCM
3
Nantahala Capital Management
Connecticut
$4.95M -$9.87K -3,488 -0.2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.9M -$170K -60,179 -3%
CC
5
Commodore Capital
New York
$3.94M – – –
SFM
6
Sphera Funds Management
Israel
$1.98M -$50.9K -18,000 -2%
JP Morgan Chase
7
JP Morgan Chase
New York
$1.88M -$60.5K -21,368 -3%
IC
8
Ikarian Capital
Texas
$1.5M +$1.48M +524,087 +675%
DP
9
Diadema Partners
New Jersey
$1.41M +$349K +123,455 +28%
ACM
10
ADAR1 Capital Management
Texas
$1.05M +$847K +299,304 +246%
BlackRock
11
BlackRock
New York
$1.04M +$13.5K +4,785 +1%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$676K +$37.5K +13,261 +5%
AC
13
Almitas Capital
California
$637K – – –
BFM
14
Boothbay Fund Management
New York
$445K +$440K +155,443 +693%
BCM
15
BML Capital Management
Indiana
$375K – – –
AI
16
AdvisorShares Investments
Maryland
$372K +$168K +59,304 +59%
PAP
17
Persistent Asset Partners
Hong Kong
$304K – – –
Two Sigma Investments
18
Two Sigma Investments
New York
$281K -$70.3K -24,827 -18%
William Blair & Company
19
William Blair & Company
Illinois
$252K +$6.79K +2,400 +2%
State Street
20
State Street
Massachusetts
$242K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$162K -$88.1K -31,125 -32%
Morgan Stanley
22
Morgan Stanley
New York
$128K +$96.8K +34,193 +200%
Northern Trust
23
Northern Trust
Illinois
$120K +$8.16K +2,882 +6%
American Century Companies
24
American Century Companies
Missouri
$77.7K +$3K +1,061 +4%
PWM
25
Prosperity Wealth Management
California
$69K -$4.67K -1,650 -6%
1
2 3

VTGN Hedge Fund Activity: Q1 2025 in Review

48 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2025, worth a combined $39M — down 13% from $44.9M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of VTGN and 3 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 12 added.

The largest buyer was Ikarian Capital, adding an estimated $1.48M. The largest seller was Goldman Sachs, exiting entirely with an estimated $574K sold.

  • 48 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2025, down from 54 in Q4 2024.
  • Funds reported $39M of VistaGen Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
  • 3 funds opened new VistaGen Therapeutics positions in Q1 2025 and 9 closed out, a net change of -6 holders.
  • The largest VistaGen Therapeutics buyer in Q1 2025 was Ikarian Capital, an estimated $1.48M added.
  • The largest VistaGen Therapeutics seller in Q1 2025 was Goldman Sachs, an estimated $574K sold.

Based on aggregated 13F filings for Q1 2025.